Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the U.S. Preventive Services Task Force

Annals of Internal Medicine

Volumn 142, Issue 10, 2005, Pages 855-860

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; GESTAGEN; PLACEBO;

BREAST CANCER; CHOLECYSTITIS; CLINICAL TRIAL; COGNITIVE DEFECT; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DEMENTIA; ENDOMETRIUM CANCER; FRACTURE; HEART INFARCTION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; MENOPAUSAL SYNDROME; META ANALYSIS; OSTEOPOROSIS; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIDE EFFECT; STROKE; SUBARACHNOID HEMORRHAGE; THROMBOEMBOLISM; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 18644363797     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-142-10-200505170-00011     Document Type: Review

References (30)

1. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women; recommendations and rationale. Ann Intern Med. 2002;137:526-8.
2. Sheridan SL, Harris RP, Woolf SH. Shared decision making about screening and chemoprevention, a suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med. 2004;26:56-66.
3. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-37.
4. American Cancer Society. Cancer Facts & Figure 2004. Accessed at www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf on 19 August 2004.
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33.
6. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-12.
7. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285:2891-7.
8. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:58-66.
9. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106:574-82.
10. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419-27.
11. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-93.
12. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997;127:973-80.
13. Humphrey L, Takano L, Chan B. Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease. Systematic Evidence Review no. 10. Prepared by the Oregon Health & Science Evidence-based Practice Center under contract no. 290-97-0018. 2002, Available at www.ahrq.gov/clinic/serfiles.htm#hrt-cardio. Accessed August 2004.
14. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002;137:273-84.
15. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:680-90.
16. Miller J, Chan B, Nelson H. Hormone Replacement Therapy and Risk of Venous Thromboembolism. Systematic Evidence Review no. 11. Prepared by the Oregon Health & Science Evidence-based Practice Center under contract no. 290-97-0018. 2002. Available at www.ahrq.gov/clinic/serfiles.htm#hrtrisk. Accessed August 2004.
17. LeBlanc E, Chan B, Nelson H. Hormone Replacement Therapy and Cognition. Systematic Evidence Review no. 13. Prepared by the Oregon Health & Science Evidence-based Practice Center under contract no. 290-97-0018, 2002. Available at www.ahrq.gov/clinic/serfiles.htm#hrtcog. Accessed August 2004.
18. Espeland MA, Rapp SR, Shumafeer SA, Brunner R, Manson JE, Sherwin BB, et al. Conjugated equine estrogens and global cognitive function in post-menopausal women: Women's Health Inidative Memory Study. JAMA. 2004;291:2959-68.
19. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogeris and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2947-58.
20. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304-13.
21. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002;288:334-41.
22. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women, JAMA. 2001;285:1460-5.
23. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer. 1996;67:327-32.
24. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol. 1994;83:5-11.
25. Simon JA, Hunninghake DB, Agarwal SK, Lin F, Cauley JA, Ireland CC, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in post-menopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2001;135:493-501.
26. ACOG Task Force on Hormone Therapy, Hormone Therapy, Obstet Gynecol. 2004;104(4 Suppl):1S-131S.
27. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672-93.
28. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause. 2004;11:589-600.
29. Abramson BL. Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease. Recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ. 2004;170:1388-9.
30. Wathen CN, Feig DS, Feightner JW, Abramson BL, Cheung AM. Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ. 2004;170:1535-7.